WHO Cherry-Picked Data on Pesticide, Investigation Finds

A group evaluating glyphosate’s cancer risk omitted evidence that the chemical is not carcinogenic.

Written byAshley P. Taylor
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

PIXABAY, SBJ04769Update (October 26): In a statement published October 24, the IARC “rejects these false claims” that it cherry-picked data on glyphosate. IARC explains that the differences between the draft document and the report center around a review paper coauthored by a Monsanto scientist: “. . . the Working Group considered that the review article did not provide adequate information for independent evaluation of the conclusions reached by the Monsanto scientist and other authors; consequently, the draft was revised, and the text in the published Monograph is the consensus opinion of the Working Group.”

IARC stands behind its conclusions.

In writing a report about the cancer risk of glyphosate, a key ingredient in Monsanto’s weed killer Roundup, the World Health Organization (WHO) edited out references to evidence that the pesticide does not cause cancer in animals, Reuters reports in a story published yesterday (October 19).

The original WHO report, issued in 2015 by the International Agency for Research on Cancer (IARC), a semiautonomous group within the WHO, concluded that glyphosate was a “Group 2a carcinogen, a substance that probably causes cancer in people,” according to Reuters. An investigation by Reuters finds that IARC redacted evidence to the contrary from their report.

“IARC members manipulated and distorted scientific data” in the glyphosate report, Scott Partridge, Monsanto’s vice president of global ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies